- **Orders received** increased by 13% to SEK 3,737 million (3,314)
- **Net sales** increased by 15% to SEK 3,415 million (2,975)
- **Profit before tax** increased by 9% to SEK 286 million (262)
- **Net profit** rose by 6% to SEK 203 million (191)
- **Earning per share** increased 8% to SEK 1.00 (0.93)
- **EBITA-result** increased by 34% to SEK 427 million (320)
- **Cash flow from operating activities** rose by 44% till SEK 871 million (603)
- **Huntleigh integration proceeding according to plan**
- **Earnings outlook remains favourable for the year**

First quarter 2007

All business areas have increased EBITA-result and –margin in the period despite a modest improvement of sales growth. The demand is still good and the integration of Huntleigh is proceeding according to plan.

Order received

Orders received by the Group increased by 13% during the quarter. Demand for the Group's products remained favourable, although organic orders received for the period remaining at the same level as the preceding year. As announced earlier, a number of major orders were booked in Ontario, Canada, in the first quarter of 2006. Adjusted for these orders, the underlying organic growth in orders received was 3.2%.

For Medical Systems, orders received decreased compared with the strong first quarter of 2006, when the volume trend was particularly strong in the US. The trend in other geographic regions for the business area was generally positive.

Organic growth in orders received for Infection Control was 4%. Similar to Medical Systems, the trend in North America was weaker.

Within Extended Care, organic orders received were on a par with the corresponding period in the preceding year. Adjusted for the above-mentioned orders in Ontario, the trend in orders received remained favourable and grew organically by 10%. The new acquisition, Huntleigh, which was consolidated in the Group from 1 February 2007, is not included in the organic order statistics, but the order trend for Huntleigh can be viewed as seasonally normal.

Results

Consolidated profit before tax for the first quarter increased by 9% and totalled SEK 285.9 million (261.6). The profit increase is principally an effect of strengthened gross margins, since the organic volume growth was modest during the period. The Group's EBITA margin improved by 1.7% and amounted to

12.5%. Restructuring costs of SEK 50 million (46) are included in earnings for the quarter.

Medical Systems increased its operating profit (EBITA) by a healthy 24% and the EBITA margin continued to strengthen during the period. Medical Systems continued to demonstrate improved gross margins as a result of good price discipline and a favourable product mix.

Infection Control's operating profit was on a level with the preceding year, while the EBIT margin was somewhat better. Organically, invoicing volumes were in line with the same period in 2006.

Extended Care recorded highly favourable profit growth for the period and operating profit increased by 66%. The EBITA margin was strengthened, even including Huntleigh and restructuring costs related to the Huntleigh acquisition totalling SEK 50 million. The efficiency enhancements implemented by Extended Care's production structure in 2006 had a positive impact on earnings and made up for the lower revenues related to the Ontario deliveries in the first quarter of 2006.

The Group's operational cash flow continued to develop well and amounted to SEK 871 million (603), an increase of 44%.

Outlook

Despite a somewhat weaker trend in orders received at the beginning of the year, the Group's assessment is that the volume outlook will remain positive. Demand remains favourable in North America and in several developing markets, at the same time as the demand scenario in Europe is at a high and stable level. The order book is at a particularly favourable level compared with the 2006.

Medical Systems anticipates a continued favourable volume trend during the year as a result of investments made both within the market organisation and product development. The gross margin continues to strengthen as a result of efficiency enhancements, mainly within Cardiopulmonary, and implemented product launches.

Infection Control also forecasts a favourable volume trend during the year as a result of the expansion of the market organisation, particularly in emerging markets, and the many product launches conducted in the last six months of 2006. Lower nonrecurring costs and increased synergies derived from the La Cahlene acquisition contributed to a rising EBITA margin.

Extended Care's volume growth will improve during the latter part of the year, since major investments in Ontario, Canada, and nonrecurring volume effects in the aftermath of the earlier FDA embargo, were completed in the second quarter of 2006. The underlying and normalised volume growth is expected to be in line with the business area's long-term growth ambitions. The restructuring activities conducted by patient-handling production will result in improved gross margins. For Huntleigh, which was consolidated from 1 February of this year, the Group expects a positive contribution to consolidated profit before tax, excluding restructuring costs totalling SEK 250 million for the current year.

On the whole, the Group's assessment of its earnings outlook has not changed since the most recent report and the outlook for 2007 is deemed favourable. The Group will continue to invest in the expansion of its market organisation and in the development of new products, albeit at a lower pace than during 2006. The

EBITA margin for the Group in its entirety will improve, including Huntleigh, but excluding restructuring costs related to Huntleigh's integration.

Business area Medical Systems

Order received

Orders received per market	**2007** **3 Mon**	2006 3 Mon	*Change adjusted for curr.flucs.&corp.acqs.*
Europe	**797.9**	764.2	*6.0%*
USA and Canada	**239.2**	340.3	*-21.8%*
Asia and Australia	**201.9**	193.9	*11.0%*
Rest of the world	**89.9**	97.5	*-14.9%*
Business area total	**1,328.9**	1,395.9	*-1.6%*

Organic orders received decreased by 1.6% during the period. The decrease was attributable to the trend in North America, where orders received fell by 22% compared with the particularly strong first quarter in the preceding year, when orders received rose by 40%. Nevertheless, the assessment is that the demand situation will remain favourable in North America.

In Europe, orders received remained favourable with positive growth in Scandinavia, the UK, Southern Europe and Eastern Europe. In German-speaking markets, orders received were slightly lower than in the preceding year, which was also the case for the Benelux region.

In emerging markets, orders received were favourable in Southeast Asia and the Middle East. In Latin America, volumes remained at a similar level as the preceding year, while orders received in Africa demonstrated a falling trend.

Results

	2007 **3 Mon**	2006 3 Mon	*Change*	2006 FY
Net sales, SEK million	**1,272.5**	1,262.1	*0.8%*	5,542.1
adjusted for currency flucs.& corp.acqs			*4.3%*	
Gross profit	**704.2**	616.6	*14.2%*	2,783.8
Gross margin %	***55.3%***	*48.9%*	*6.4%*	*50.2%*
Operating cost, SEK million	**-504.8**	-455.7	*10.8%*	-1,894.5
EBITA before restructuring and integration costs	**201.1**	162.4	*23.8%*	895.7
EBITA margin %	***15.8%***	*12.9%*	*2.9%*	16.2%
Restructuring and integration costs	**–**	–	*0.0%*	–
EBIT	**199.4**	160.9	*23.9%*	889.3
EBIT margin %	***15.7%***	*12.7%*	*3.0%*	*16.0%*

Operating profit (EBITA) increased by 24% during the period and amounted to SEK 201.1 million (162.4). The gross margin trend remains highly favourable and is attributable to a good product mix, price control and efficiency gains within production. The increase in overheads is well in line with the continued investments being made. The EBITA margin amounted to a healthy 15.8% during the quarter.

Activities

Product development and product launches

Medical Systems continues to invest strongly in the development of new products. Investments are particularly significant within the Critical Care and Cardiopulmonary divisions.

The launch of the new NAVA ventilator technology is proceeding according to plan. The work is principally focused around a number of clinical trials aimed at demonstrating that the use of NAVA technology can shorten the duration of treatment in intensive-care units, thereby reducing medical expenses. NAVA technology has already had a positive impact on sales of ventilators, although, sales of the NAVA software and disposables are not expected to gain momentum until the end of the year and onward.

A major development project is being pursued within Critical Care aimed at developing a new generation of anaesthesia machines with clear competitive advantages. It is anticipated that deliveries of the new product family on a commercial scale can commence in mid-2008. The new product family is expected to have the potential to capture a significant market share in the anaesthesia market, which is valued at about SEK 5,500 million annually.

Within Cardiopulmonary, the launch is underway of the new family of oxygenators, which will gradually replace the existing oxygenator program during 2007 and 2008. The product program, which has a modular structure, is both more competitive and offers better clinical performance that its predecessor. During the period, development work on a new generation of heart-lung machines commenced. The development project, will not only replace existing heart-lung machines, but will also have applications within interventional cardiology and within acute cardiac care.

New production structure within Cardiopulmonary

The production unit under construction in Turkey was put into operation during the quarter. Over the next two years, the aim is to transfer the personnel-intensive production of disposables from Germany to the Turkish unit, while efficiency in the more capital-intensive production will be enhanced in its current location in Germany.

Production in China

As a result of Medical System's ambitions to expand local production in China, both as part of the work to better serve the local market, but also to strengthen the business area's competitiveness, a decision was made during the quarter to construct a new plant in China. The size of the plant, which will be constructed adjacent to the Group's existing plant in Suzhou, will be approximately 6,000 square meters. Ceiling service units are already produced in China. The production of surgical lights is expected to commence at the end of the current year. In 2008, the aim is to also manufacture basic surgical tables for a global market in the Chinese plant.

Business area Infection Control

Order received

Orders received per market	2007 3 Mon	2006 3 Mon	Change adjusted for curr.flucs.&corp.acqs.
Europe	**625.6**	565.0	*11.9%*
USA and Canada	**300.3**	356.6	*-6.1%*
Asia and Australia	**110.4**	106.0	*7.6%*
Rest of the world	**10.0**	26.5	*-43.6%*
Business area total	**1,046.3**	1,054.1	*4.4%*

Orders received increased organically by SEK 4.4% during the quarter. Similar to Medical Systems, the trend was weaker in North America, particularly with regard to the Canadian market. Infection Control, like Medical Systems, expects the demand and the volume outlook in North America to remain favourable.

In Europe, volume growth remained favourable with an organic volume increase of 12%. In the markets in the UK, Southern Europe, Eastern Europe and in German-speaking countries, the trend was particularly good, while the trend in Scandinavia was weaker.

In emerging markets, orders received were more mixed during the period, with favourable growth in the Middle East and in Southeast Asia, while Africa and Latin America were weaker.

Results

	2007 3 Mon	2006 3 Mon	Change	2006 FY
Net sales, SEK million	**852.2**	894.0	-4.7%	4,261.8
adjusted for currency flucs.& corp.acqs			0.1%	
Gross profit	**332.6**	349.7	-4.9%	1,605.4
Gross margin %	***39.0%***	*39.1%*	-0.1%	*37.7%*
Operating cost, SEK million	**-247.7**	-264.7	-6.4%	-1,043.6
EBITA before restructuring and integration costs	**88.7**	88.8	-0.1%	577.0
EBITA margin %	***10.4%***	*9.9%*	0.5%	*13.5%*
Restructuring and integration costs	**-0.1**	-5.4	-98.1%	-9.8
EBIT	**84.8**	79.6	6.5%	552.0
EBIT margin %	***10.0%***	*8.9%*	1.1%	*13.0%*

Operating profit (EBITA) amounted to SEK 88.7 million and was on a par with the corresponding period in the preceding year. The improved operating profit was mainly attributable to a reduction in operating expenses.

Activities

Logistics project

Infection Control's logistics project, which is aimed at enhancing efficiency of order and delivery procedures as well as reducing tied-up capital, is proceeding according to plan. When fully implemented, the project will result in annual savings of about SEK 50 million.

La Cahlène

The integration of La Cahlène, which has been included in the business area since mid-2005, was concluded during the quarter.

Production in China

Plans to locate production of pressure vessels for sterilizers to the business area's production unit in Souzou are proceeding according to plan. It will be possible to commence local production of pressure vessels in the fourth quarter. This is an important step in the process to further reduce production costs.

Outsourcing of sterile centres in the United Kingdom

During the first quarter, Infection Control booked its first major order within the framework of the program initiated by the health authority in the UK, the NHS, (National Health Service), to construct a number of large sterilization centres, known as supercentres. As previously announced, the NHS has extensive plans to construct a large number of centres, which will supply public hospitals with sterile instruments on an outsourcing basis. Infection Control expects to be able to secure a significant share of the centres planned in the next few years.

Business area Extended Care

Order received

Orders received per market	2007 3 Mon	2006 3 Mon	Change adjusted for curr.flucs.&corp.acqs.
Europe	**876.9**	487.7	*6.0%*
USA and Canada	**387.4**	342.0	*-13.3%*
Asia and Australia	**80.6**	20.7	*11.4%*
Rest of the world	**16.7**	1.6	*-68.4%*
Business area total	**1,361.6**	852.0	*-1.7%*

Orders received decreased organically by 1.7% during the quarter. Adjusted for the major orders in Ontario, Canada, registered during the corresponding quarter in the preceding year, orders received increased by 10.3%, which is in line with the improved volume trend that could be observed since mid-2006. The volume trend in Europe was stable with favourable increases in Scandinavia, Southern Europe, the Benelux countries and German-speaking markets. In the UK, orders received were on a par with the preceding year.

In North America, orders received remained favourable in the US, where organic growth was an excellent 14%, while the trend in Canada was weaker for reasons specified above.

In emerging markets, total orders received were in line with 2006.

For Huntleigh, which is not yet included in the organic growth figures and which was consolidated from 1 February, orders received were normal for the period.

Results

	2007 3 Mon	2006 3 Mon	Change	2006 FY
Net sales, SEK million	**1,290.1**	807.1	*59.8%*	3,182.7
adjusted for currency flucs.& corp.acqs			*-4.1%*	
Gross profit	**627.4**	361.3	*73.7%*	1,500.2
Gross margin %	***48.6%***	*44.8%*	*3.8%*	*47.1%*
Operating cost, SEK million	**-461.6**	-251.6	*83.5%*	-977.1
EBITA before restructuring and integration costs	**188.2**	113.7	*65.5%*	538.5
EBITA margin %	***14.6%***	*14.1%*	*0.5%*	*16.9%*
Restructuring and integration costs	**-50.4**	-40.7	*23.8%*	-35.4
EBIT	**115.4**	69.0	*67.2%*	487.7
EBIT margin %	***8.9%***	*8.5%*	*0.4%*	*15.3%*

Operating profit (EBITA) amounted to SEK 188.2 million, an increase of 65.5% compared with the first quarter of the preceding year. Invoicing was organically lower than the corresponding period in the preceding year as a result of lower delivery volumes in Canada (Ontario). The improved gross margin is primarily an effect of the enhancements in production efficiency implemented within the patient-handling area in 2006. The Huntleigh acquisition, which is included in the business area from February, has developed according to plan. Restructuring costs totalling SEK 50 million pertaining to the Huntleigh integration were charged against earnings for the quarter.

Activities

Huntleigh integration

The integration of Huntleigh, which commenced immediately following year-end, is proceeding according to plan. Since 1 March, a joint organisation with a common management structure has been established. The purpose of the new organisation is to create an operation that can stimulate the development of synergies, both in terms of costs and sales, between Huntleigh and Extended Care. As announced in a separate press release, Extended Care anticipates that it should be possible to achieve existing profitability and growth targets for the business area not later than 2009. Sales synergies that will ensure rapid and stable growth of approximately 7% will have an impact from 2008 and onward. Cost synergies will contribute to earnings already during the current year of between SEK 50 million and SEK 60 million and will exceed SEK 300 million when fully implemented in 2009/2010. Costs for the announced structural program are expected to total about SEK 400 million.

Product development

The new generation of passive patient lifts, currently under development, is proceeding according to plan. The new product family is based on three platforms and replaces seven existing product platforms. The new products are expected to be significantly more functional and cost-efficient than the existing product program. The launch of the new product platform will be initiated in the second half of 2007 and continue until year-end 2008.

Other information

Accounting	This interim report was prepared in accordance with IAS 34 Interim Financial Reporting. The accounting and calculation principles used in the interim report are identical to those used in the most recent annual report. This report is unaudited.
Future-oriented information	This report contains future-oriented information based on the current expectations of Getinge's Group management. Although the management deems that the expectations presented by such future-oriented information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the future-oriented information due to such factors as changed conditions regarding business cycles, market and competition, changes in legal requirements and other political measures, and fluctuations in exchange rates.
Next report	The next report from the Getinge Group (second quarter of 2007) will be published on 16 July 2007.
Tele-conference	A tele-conference will be held today at 2:00 p.m. Swedish time. To participate, please call: from Sweden 08-50 520 114, password: Getinge from outside Sweden +44 (0)20 7162 0125, password: Getinge A recorded version of the conference will be available for five working days at the following numbers: Sweden 08-505 203 33, access code: 746530 UK +44 (0)20 7031 4046, access code: 746530

Getinge 19 April 2007

Johan Malmquist
President

Getinge AB
Box 69, 310 44 Getinge
Telephone +46 (0)35 15 55 00. Fax +46 (0)35 549 52
email info@getinge.com
Company reg. No. 556408-5032
www.getinge.com

Income statement

SEK million	2007 3 Mon	2006 3 Mon	Change	2006 FY
Net sales	**3,414.8**	2,974.8	*14.8%*	13,001.3
Cost of goods sold [4]	**-1,750.5**	-1,643.8	*6.5%*	-7,107.6
Gross profit	**1,664.3**	1,331.0	*25.0%*	5,893.7
Gross margin	*48.7%*	*44.7%*	*4.0%*	*45.3%*
Selling expenses [4]	**-715.4**	-595.3	*20.2%*	-2,467.0
Administrative expenses [4]	**-390.4**	-300.4	*30.0%*	-1,191.1
Research & development costs [1)]	**-101.9**	-81.6	*24.9%*	-282.1
Restructuring and integration costs	**-50.5**	-46.1	*9.5%*	-45.2
Other operating income and expenses	**-6.4**	3.2	*-300.0%*	28.0
Operating profit [2)]	**399.7**	310.8	*28.6%*	1,936.3
Operating margin	*11.7%*	*10.4%*	*13%*	*14.9%*
Financial net	**-113.8**	-49.2		-208.2
Profit before tax	**285.9**	261.6	*9.3%*	1,728.1
Taxes	**-82.8**	-70.6		-468.7
Net profit	**203.1**	191.0	*6.3%*	1,259.4
Attributable to:				
Parent company's shareholders	**202.8**	187.1		1,254.0
Minority interest	**0.3**	3.9		5.4
Net profit	**203.1**	191.0		1,259.4
Earnings per share, SEK [3)]	**1.00**	0.93	*7.5%*	6.21

1) Development costs totalling SEK 54.8 (31.7) million have been capitalised during the quarter.

2) Operating profit is charged with

— amort. Intangibles on acquired companies	***-27.7***	*-9.3*		*-36.9*
— amort. intangibles	***-17.6***	*-9.8*		*-47.1*
— depr. on other fixed assets	***-95.8***	*-71.1*		*-250.1*
	-141.1	*-90.2*		*-334.1*

3) There are no dilutions

4) Due to reclassification of certain costs, some transfer have been made in the comparision from cost of goods sold to operating costs.

Quarterly results

SEK million	2005 Q 1	2005 Q 2	2005 Q 3	2005 Q 4	2006 Q 1	2006 Q 2	2006 Q 3	2006 Q 4	2007 Q 1
Net sales	2,525.2	2,739.0	2,727.4	3,888.8	2,974.8	3,147.7	2,883.2	3,995.6	3,414.8
Cost of goods sold	-1,348.7	-1,518.7	-1,524.4	-2,163.1	-1,643.8	-1,725.4	-1,618.6	-2,119.8	-1,750.5
Gross profit	1,176.5	1,220.3	1,203.0	1,725.7	1,331.0	1,422.3	1,264.6	1,875.8	1,664.3
Operating cost	-814.1	-866.7	-856.4	-985.5	-1,020.2	-1,004.4	-897.1	-1,025.7	-1,264.6
Operating profit	362.4	353.6	346.6	740.2	310.8	417.9	367.5	840.1	399.7
Financial net	-49.5	-49.4	-55.4	-47.1	-49.2	-53.6	-52.9	-52.5	-113.8
Profit before tax	312.9	304.2	291.2	693.1	261.6	364.3	314.6	787.6	285.9
Taxes	-87.6	-85.2	-81.5	-197.4	-70.6	-98.4	-84.9	-214.8	-82.8
Profit after tax	225.3	219.0	209.7	495.7	191.0	265.9	229.7	572.8	203.1

Balance sheet

Assets SEK million	**2007 31 March**	2006 31 March	2006 31 Dec
Intangible fixed assets	**10,422.9**	5,496.7	5,516.1
Tangible fixed assets	**2,352.9**	1,475.9	1,397.2
Financial assets	**751.1**	668.0	1,876.2
Stock-in-trade	**2,955.9**	2,322.7	2,082.4
Current receivables	**4,793.7**	3,682.8	4,331.5
Cash and cash equivalents	**931.4**	688.9	673.3
Total assets	**22,207.9**	14,335.0	15,876.7
Shareholders' equity & Liabilities			
Shareholders' equity	**6,267.0**	5,555.8	6,004.8
Long-term liabilities	**11,442.3**	5,831.5	6,567.6
Current liabilities	**4,498.6**	2,947.7	3,304.3
Total Equity & Liabilities	**22,207.9**	14,335.0	15,876.7

Cash flow statement

SEK million	2007 3 Mon	2006 3 Mon	2006 FY
Current activities			
Operating profit	**399.7**	310.8	1,936.3
Adjustment for items not included in cash flow	**171.6**	123.1	277.2
Financial items	**-113.8**	-49.2	-203.4
Taxes paid	**-125.0**	-131.1	-387.4
Cash flow before changes in working capital	**332.5**	253.6	1,622.7
Changes in working capital			
Stock-in-trade	**-385.4**	-193.5	-75.1
Rental equipment	**-11.3**	3.6	-10.5
Current receivables	**476.8**	266.9	-483.8
Current operating liabilities	**219.4**	92.0	451.2
Cash flow from operations	**632.0**	422.6	1,504.5
Investments			
Acquisition of subsidiaries	**-5,514.4**	-4.4	-272.3
Investments in intangible fixed assets	**-59.9**	-32.7	-205.6
Investments in tangible fixed assets	**-82.4**	-60.2	-315.4
Disposal of tangible fixed assets	**5.0**	0.9	157.3
Cash flow from investments	**-5,651.7**	-96.4	-636.0
Financial activities			
Change in interest-bearing debt	**4,194.7**	-321.3	568.2
Change in long-term receivables	**1,225.6**	-24.6	-1,276.9
Minority redemption	**-**	-	51.0
Dividend paid	**-**	-	-405.4
Cash flow from financial activities	**5,420.3**	-345.9	-1,063.1
Cash flow for the period	**400.6**	-19.7	-194.6
Cash and cash equivalents at begin of the year	**673.3**	683.6	683.6
Translation differences	**-142.5**	25.0	184.3
Cash and cash equivalents at end of the period	**931.4**	688.9	673.3

Operating cash flow statement

SEK million	**2007 3 Mon**	2006 3 Mon	2006 FY
Business activities			
Operating profit	**399.7**	310.8	1,936.3
Adjustment for items not included in cash flow	**171.6**	123.1	277.2
	571.3	433.9	2,213.5
Changes in operating capital			
Stock-in-trade	**-385.4**	-193.5	-75.1
Rental equipment	**-11.3**	3.6	-10.5
Current receivables	**476.8**	266.9	-483.8
Current liabilities	**219.4**	92.0	451.2
Operating cash flow	**870.8**	602.9	2,095.3

Net interest-bearing debt

SEK million	**2007 31 March**	2006 31 March	2006 31 Dec
Debt to credit institutions	**9,119.4**	3,771.3	4,609.5
Provisions for pensions, interest-bearing	**1,920.7**	1,686.3	1,638.9
Less liquid funds	**-931.4**	-688.9	-673.3
Net interest-bearing debt	**10,108.7**	4,768.7	5,575.1

Changes to shareholders' equity

SEK million	**2007 31 March**	2006 31 March	2006 31 Dec
Shareholders' equity – opening balance	**6,004.8**	5,381.3	5,381.3
Dividend distributed	**–**	–	-403.7
Dividend to minority	**–**	–	-1.7
Change of reserve hedge accounting	**-63.2**	54.9	159.9
Change of minority		–	-51.0
Translation differences	**122.3**	-71.4	-339.4
Net profit	**203.1**	191.0	1,259.4
Shareholders' equity – closing balance	**6,267.0**	5,555.8	6,004.8
Attributable to:			
Parent company's shareholders	**6,241.3**	5,479.8	5,983.3
Minority interest	**25.7**	76.0	21.5
Total shareholders' equity	**6,267.0**	5,555.8	6,004.8

Key figures

	2007 3 Mon	2006 3 Mon	Change	2006 FY
Orders received, SEK million	**3,736.8**	3,313.7	*12.8%*	13,316.4
adjusted for currency flucs.& corp.acqs			*0.3%*	
Net sales, SEK million	**3,414.8**	2,974.8	*14.8%*	13,001.3
adjusted for currency flucs.& corp.acqs			*0.7%*	
EBITA	**427.3**	320.0	*33.5%*	1,973.3
EBITA margin	**12.5%**	10.8%	*17%*	15.2%
Earnings per share after full tax, SEK	**1.00**	0.93	*7.5%*	6.21
Nmb of shares, thousands	**201,874**	201,874		201,874
Operating capital, SEK million	**10,222.6**	9,903.3	*3.2%*	10,217.4
Return on operating capital, per cent	**19.3%**	18.5%	*0.8%*	19.2%
Return on equity, per cent	**22.1%**	22.3%	*-0.2%*	22.6%
Net debt/equity ratio, multiple	**1.61**	0.86	*0.75*	0.93
Interest cover, multiple	**7.2**	8.2	*-10*	9.0
Equity/assets ratio, per cent	**28.2%**	38.8%	*-10.6%*	37.8%
Equity per share, SEK	**30.92**	27.14	*13.9%*	29.64
Number of employees at the period's end	**10,343**	7,382		7,531

Companies acquired in 2007

Huntleigh Technology PLC.

During the first quarter of 2007, the Getinge Group acquired 78.48% of the shares in Huntleigh Technology PLC and now owns 100% of shares. Huntleigh is active within the areas of special mattresses for the treatment of pressure ulcers, beds for intensive, specialist and elderly care, compression products that prevent the onset of thrombosis and facilitate the treatment of lymphoedema and pressure ulcers, and equipment for obstetric and vascular diagnostics.

At the date of acquisition, the company's assets totalled approximately SEK 2,370 million and liabilities SEK 990 million. The agreed purchase price for 100% of shares amounted to about SEK 5,630 million. In the study intended to allocate the purchase price, surplus value in intangible and tangible fixed assets was calculated at about SEK 1,520 million.

In 2006, sales amounted to approximately SEK 3,000 million, EBIT to about SEK 390 million and the number of employees to approximately 2,700.

Huntleigh was consolidated as of February 2007.

Definitions

EBIT	Operating profit
EBITA	Operating profit before amortsation of intangible fixed assets identified upon business acquisitions.